Contents - pharmaphorum

Editions

Contact

1. Cover
2. Introduction
3. Contents
4. Why pharma needs honest patient dialogue
5. Did cancer clinical trials stay on track at ASCO 2019?
6. Getting patients round the virtual table
7. Sign-up for pharma news alerts
8. Cytel Company Profile
9. Adapting for the future of oncology trials
10. Revealing the true value of new cancer drugs
11. Discover the power of strategic partnerships
12. Smarter thinking about pharma marketing
13. Moving from autologous to allogeneic ACT
14. The promise and pitfalls of molecular testing
15. Subscribe to future Deep Dive issues
16. Contact the Deep Dive team

Open magazine

Editions

Contact

Hi there!

Click here and sign up now

Contents: Deep Dive – Oncology and ASCO 2019

Cover

Oncology and ASCO 2019

Click here

Introduction

Welcome from the Editor

Click here

Why pharma needs honest patient dialogue

Astellas Pharma US president Percival Barretto-Ko talks with Paul Tunnah about drug pricing, collaboration and improving the patient experience

Click here

Did cancer clinical trials stay on track at ASCO 2019?

pharmaphorum spoke with three experts from Kantar to discuss the most interesting developments and trends in cancer that emerged at this year’s ASCO conference

Click here

Getting patients round the virtual table

If pharma wants to be truly patient centric, it needs to be talking to patients – and digital, asynchronous engagement could be one solution to overcome the barriers that still exist

Click here

The pharma world at your fingertips

Daily News from pharmaphorum – insights and analysis on the big trends shaping healthcare and the pharmaceutical industry

Click here

Company Spotlight: Cytel

Turning clinical and real-world data into evidence to minimise risk and accelerate drug development

Click here

Adapting for the future of clinical trials

Cytel is at the forefront of rapid changes in oncology R&D. We spoke with the team to find out why oncology trials are not where they need to be and how research needs to evolve

Click here

Revealing the true value of new cancer drugs to payers

It can be difficult for payers to keep abreast of the benefits associated with new drugs. New ways of demonstrating value are needed to capture clinical mechanisms

Click here

Discover the power of strategic partnerships for flow cytometry

Flow cytometry is a critical tool in assessing the efficacy of targeted therapies, such as immuno-therapy, but detecting the presence of complex molecules can be challenging without strategic partnerships

Click here

Smarter thinking about pharmaceutical marketing

Robb DeFilippis, from end-to-end global creative production and sourcing partner Tag, discusses how a more effective multichannel pharma marketing approach can positively affect patient outcomes

Click here

Moving from autologous to allogeneic ACT paradigms

Adoptive Cellular Transfer approaches have the possibilities of therapies with reduced safety concerns, a higher therapeutic index, as well as breadth of targets including solid tumours

Click here

The promise and pitfalls of molecular testing in oncology

Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain that frustrate both physicians and patients. Central to this is how to use the large amounts of genetic data now available

Click here